Nuvaira
PrivateLast Round
Early Stage
VC
Feb 20, 2026
Total Funding Raised
$150.98M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Nuvaira operates in Healthcare & Life Sciences and is based in Maple Grove, Minnesota. Its latest recorded funding round was a Seed round in August 2025.
Nuvaira is a medical technology company that develops a novel catheter-based device aimed at improving outcomes for patients with obstructive lung diseases by treating overactive airway nerves.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nuvaira Comparables
Compare Nuvaira with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CSA Medical | 89% | |
| Ryme Medical | 88% | |
| Apreo Health | 86% |
For institutional investors. Book with your work email.
Nuvaira Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Stage VC | Feb 20, 2026 | ||||
| Seed | Aug 25, 2025 | ||||
| Growth Equity | Apr 24, 2024 | ||||
| VC Round | Nov 28, 2023 | ||||
| Series E | Feb 11, 2019 | ||||
Series D | Apr 3, 2014 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nuvaira Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Vertex Ventures HC | Series E |
| Lightstone Ventures | Series E |
| Split Rock Partners | Series C, Series B, Series A, Series D, Series E |
| U.S. Venture Partners | Series E |
| Richard King Mellon Foundation | Series E |
| Versant Ventures | Series C, Series B, Series A, Series D, Series E |
| Advanced Technology Ventures | Series C, Series A, Series D, Series E, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 89% MoM.
- Aug 18, 2026
Grew 25% QoQ, from 16 to 20 employees.
For institutional investors. Book with your work email.
Nuvaira Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nuvaira's valuation, stock price, and market status.
Is Nuvaira a public or private company?
Nuvaira is a private company.
What is the current stock price of Nuvaira?
Nuvaira is a private company, so its shares have no public market price. Caplight tracks Nuvaira's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nuvaira worth (valuation)?
Valuation information for Nuvaira is not publicly available.
Can I buy Nuvaira stock?
Nuvaira shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nuvaira's last funding round?
Nuvaira's most recent funding round was Early Stage VC on February 20, 2026.
Who are the main investors in Nuvaira?
Key investors in Nuvaira include U.S. Venture Partners, Advanced Technology Ventures.
Will Nuvaira IPO soon?
No public IPO plans have been announced for Nuvaira.
How can I track Nuvaira secondary market activity?
Caplight tracks bids, offers, and trades in Nuvaira's shares on secondary markets.